Anti-infectives specialist Cidara Therapeutics Inc. said positive top-line data from Part B of its global Phase II STRIVE trial, which evaluated once-weekly use of its lead asset rezafungin acetate compared with once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis, bolstered clinical prospects of the antifungal candidate and its ongoing Phase III ReSTORE program.
On 29 July, Cidara said the Phase II STRIVE B trial of the intravenous treatment met all its objectives for...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)